Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Ablative therapy, as a local treatment modality for tumors, has an immune activating effect.
To explore the synergistic effect of microwave ablation combined with PD-1 inhibitors, this
prospective, open-label, multi-cohort, single-center clinical study was conducted. To compare
the feasibility and safety of preoperative microwave ablation alone, with or without
camrelizumab in patients with early newly diagnosed breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University